Pfizer continues work in vaccines space with new equity stake

21 June 2022
research_biotech_pharma_big

Building on the progress made via  a partnership with BioNTech (Nasdaq: BNTX), American pharma giant Pfizer (NYSE: PFE) is taking further steps to develop its vaccines business.

The company will pay 90.5 million euros ($95 million) for an 8% stake in French vaccines company Valneva (Euronext: VLA). The latter’s shares shot up nearly 35% to 12.15 euros by late morning trading.

The equity deal adds to an  existing collaboration and license agreement for Lyme disease vaccine candidate VLA15, which includes a planned Phase III study later this year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical